News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 21, 2015, 10:45 ET

New Phase III Data in Asthma Patients Show Tiotropium Improves Lung Function, Regardless of Allergic Status

 Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat® inhaler from five Phase III trials from...

Feb 12, 2015, 09:19 ET

New Survey Uncovers Emotional and Physical Impact of Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease

 People living with idiopathic pulmonary fibrosis (IPF) lack understanding of the disease, experience significant emotional burden and feel...

Feb 10, 2015, 13:15 ET
http://www.multivu.com/players/English/7401451-boehringer-ingelheim-diabetes/gallery/image/b48463d6-1153-4c1a-82f8-d34d911b945a.HR.jpg

Boehringer Ingelheim Launches Groundbreaking Initiative "Cuida tu Don" with Entertainer "Don Francisco" Aimed at Hispanics with Type 2 Diabetes

 Today, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced the launch of 'Cuida tu Don,' a national public awareness initiative...

Feb 10, 2015, 08:00 ET

Boehringer Ingelheim lanza una iniciativa innovadora "Cuida tu Don" con el animador "Don Francisco", dirigido a hispanos con diabetes tipo 2

Hoy, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) anunció el lanzamiento de 'Cuida tu Don', una iniciativa de concientización...

Feb 02, 2015, 08:30 ET
Glyxambi® (empagliflozin/linagliptin) tablet packaging 10/5 mg (left). Glyxambi® (empagliflozin/linagliptin) tablet packaging 25/5 mg (right)

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer...

Feb 02, 2015, 05:00 ET
Boehringer Ingelheim.

Leading Animal Health Company, Boehringer Ingelheim Vetmedica, Inc., Announces Website Redesign

Today, Boehringer Ingelheim Vetmedica, Inc. (BIVI), the 5th largest animal health company in the United States, announces the launch of its...

Jan 21, 2015, 09:02 ET
SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema, and to reduce exacerbations in COPD patients.

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the United States

 Boehringer Ingelheim Pharmaceuticals, Inc. announced today that SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray is now...

Jan 12, 2015, 08:00 ET

The Lancet Oncology publishes phase III data showing Gilotrif® (afatinib) extends overall survival in lung cancer patients whose tumors have the most common EGFR mutation compared with chemotherapy

 Boehringer Ingelheim today announced overall survival (OS) results were published in The Lancet Oncology from two independent Phase III...

Dec 08, 2014, 13:30 ET

New Data Show Idarucizumab* Reverses Anticoagulant Effects of Dabigatran (PRADAXA®) in Middle-Aged, Elderly and Renally Impaired Volunteers

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced phase I data that showed administration of investigational idarucizumab in healthy...

Nov 18, 2014, 10:00 ET

New Data Show Idarucizumab* Restores Wound-Site Formation of Fibrin, a Key Component of Blood Clotting, in Healthy Volunteers Given Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced phase I study sub-analyses showing that its investigational antidote idarucizumab...

Nov 18, 2014, 10:00 ET

Interim Data Reinforce Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation

Brigham and Women's Hospital and Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim findings from an analysis of two health...

Nov 17, 2014, 16:00 ET
Eli Lilly and Company logo.

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Empagliflozin tablets reduced hemoglobin A1C (a measure of average blood sugar over the past two to three months), body weight and several markers...

Nov 17, 2014, 10:00 ET

U.S. Department of Defense Study Supports Favorable Benefit-Risk Profile of Pradaxa® (dabigatran etexilate mesylate) for Reducing Stroke Risk in Non-valvular Atrial Fibrillation

Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a U.S. Department of Defense cohort analysis of the Military Health System...

Nov 17, 2014, 08:00 ET

New Survey Uncovers Critical Need to Break Down Barriers and Improve Communication and Education about the Link between Atrial Fibrillation and Devastating Impact of Stroke

Released today, a new survey of more than 1,200 physicians, patients with atrial fibrillation (AFib) and their caregivers uncovered important...

Nov 10, 2014, 08:00 ET

New Real-World Safety and Efficacy Data on Pradaxa® (dabigatran etexilate mesylate) to be Presented at American Heart Association Scientific Sessions

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that two separate comparative analyses evaluating the safety and efficacy of...

Nov 10, 2014, 08:00 ET

Boehringer Ingelheim Initiates U.S. Sites in First-Ever Global Phase III Trial of Investigational Antidote in Patients Taking PRADAXA® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of U.S. sites of the RE-VERSE AD™ trial (NCT02104947), a phase...

Nov 03, 2014, 10:00 ET

Boehringer Ingelheim Announces U.S. Filing Acceptance of New Drug Application for Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Treatment of Asthma

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for...

Nov 03, 2014, 08:00 ET

FDA Study of Medicare Patients Reaffirms Safety and Efficacy Profile of Pradaxa® (dabigatran etexilate mesylate) for NVAF

 A U.S. Food and Drug Administration (FDA) study of more than 134,000 Medicare patients found that Pradaxa® (dabigatran etexilate...

Oct 27, 2014, 09:45 ET

Boehringer Ingelheim Presents Data for the Co-Administration of Two Approved Products for COPD Patients

 Boehringer Ingelheim today presented data from the ANHELTO™ 1&2 studies (NCT01694771/NCT01696058) that evaluated the...

Oct 21, 2014, 08:30 ET
Eli Lilly and Company logo.

U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination

The U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for empagliflozin plus immediate-release...